Reports Q1 revenue $78.354M, consensus $75.86M. “The first quarter was marked by strong year-over-year NRx growth in Afrezza, substantial Tyvaso DPI-related revenues and continued progress in our Phase 3 trial of MNKD-101 in NTM lung disease,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind (MNKD) Corporation. “We expect to file for approval of Afrezza in the pediatric population this summer and to continue developing our MNKD-201 program in IPF.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue